| Edwards Dental Clinic Inc | |
|
1202 Hwy 22 Edwards MS 39066 | |
| (601) 852-2832 | |
| (601) 852-8927 |
| Full Name | Edwards Dental Clinic Inc |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 1202 Hwy 22, Edwards, Mississippi |
| Authorized Official Name and Position | Lane Gibson Clower (DMD) |
| Authorized Official Contact | 6018522832 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Edwards Dental Clinic Inc 1202 Hwy 22 Edwards MS 39066 Ph: (601) 852-2832 | Edwards Dental Clinic Inc 1202 Hwy 22 Edwards MS 39066 Ph: (601) 852-2832 |
| NPI Number | 1982740809 |
|---|---|
| Provider Enumeration Date | 01/29/2007 |
| Last Update Date | 08/22/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982740809 | NPI | - | NPPES |
| 00060458 | Other | MS | PROVIDER |
| 05730275 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 253590 (Mississippi) | Primary |
News Archive
Not all biological weapons are created equal. They are separated into categories A through C, category A biological agents being the scariest: They are easy to spread, kill effectively and call for special actions by the pubic health system. One of these worrisome organisms is anthrax, which has already received its fair share of media attention. But work in Vince Fischetti's laboratory at Rockefeller University suggests that a newly discovered protein could be used to fight anthrax infections and even decontaminate areas in which anthrax spores have been released.
Nearly 90 percent of adults use digital devices for two or more hours per day, according to The Vision Council's 2016 Digital Eye Strain Report, exposing consumers to blue light that some suggest is dangerous.
Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partner Ablynx NV has initiated additional Phase I studies with its anti-RSV Nanobody ALX-0171 using Activaero's FAVORITE inhalation approach.
Cancer Research UK has started recruiting patients for a pioneering initiative to demonstrate how genetic tests could be used within the NHS to help match cancer patients to the most appropriate treatment, while building a database of information for research into new targeted therapies.
› Verified 3 days ago